Free Trial

biote (BTMD) Stock Price, News & Analysis

-0.07 (-1.20%)
(As of 01:25 PM ET)
Today's Range
50-Day Range
52-Week Range
65,537 shs
Average Volume
107,353 shs
Market Capitalization
$357.35 million
P/E Ratio
Dividend Yield
Price Target

biote MarketRank™ Stock Analysis

Analyst Rating
3.00 Rating Score
37.5% Upside
$8.11 Price Target
Short Interest
3.25% of Float Sold Short
Dividend Strength
News Sentiment
0.73mentions of biote in the last 14 days
Based on 3 Articles This Week
Insider Trading
Proj. Earnings Growth

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.24 out of 5 stars

Medical Sector

526th out of 920 stocks

Medicinals & Botanicals Industry

4th out of 10 stocks

BTMD stock logo

About biote Stock (NASDAQ:BTMD)

biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification services; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support. It also sells dietary supplements under the Biote brand; and sterile pellet insertion kits that is used with hormone optimization therapies for male and female. The company was founded in 2012 and is headquartered in Irving, Texas.

BTMD Stock Price History

BTMD Stock News Headlines

Biote Announces Definitive Settlement with Founder
Preview: Biote's Earnings
Birmingham manufacturer to be acquired for $8.5M
Biote price target lowered by $1 at Truist, here's why
Biote names Robert Peterson as its CFO
See More Headlines
Receive BTMD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for biote and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Medicinals & botanicals
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Rating Score (0-4)
Research Coverage
5 Analysts


Net Income
$3.32 million
Pretax Margin


Sales & Book Value

Annual Sales
$185.36 million
Cash Flow
$0.52 per share
Book Value
($0.72) per share


Free Float
Market Cap
$361.69 million
Not Optionable
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Key Executives

  • Mr. Marc D. Beer (Age 59)
    Executive Chairman
    Comp: $470.18k
  • Ms. Teresa S. Weber (Age 71)
    CEO & Director
    Comp: $1.06M
  • Ms. Mary Elizabeth Conlon (Age 43)
    VP of Business Development, General Counsel & Corporate Secretary
    Comp: $552.36k
  • Ms. Mary J. Puncochar (Age 60)
    Head of Strategic Sales & Business Analytics
    Comp: $465.47k
  • Mr. Robert C. Peterson (Age 47)
    Chief Financial Officer
  • Mr. John J. Olsen (Age 67)
    Chief Information Officer
  • Mr. James Elliott Gibbs II
    Chief People Officer
  • Mr. Richard Kevin Key (Age 53)
    Chief Digital Officer
  • Mr. Jade Beutler (Age 61)
    Head of Nutraceuticals
  • Dr. Cory Rice D.O.
    Chief Clinical Advisor & Member of Medical Advisory Board

BTMD Stock Analysis - Frequently Asked Questions

Should I buy or sell biote stock right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for biote in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" BTMD shares.
View BTMD analyst ratings
or view top-rated stocks.

What is biote's stock price target for 2024?

5 Wall Street research analysts have issued 1 year price objectives for biote's shares. Their BTMD share price targets range from $6.55 to $9.00. On average, they anticipate the company's share price to reach $8.11 in the next year. This suggests a possible upside of 37.5% from the stock's current price.
View analysts price targets for BTMD
or view top-rated stocks among Wall Street analysts.

How have BTMD shares performed in 2024?

biote's stock was trading at $4.94 on January 1st, 2024. Since then, BTMD shares have increased by 19.4% and is now trading at $5.90.
View the best growth stocks for 2024 here

When is biote's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 8th 2024.
View our BTMD earnings forecast

How were biote's earnings last quarter?

biote Corp. (NASDAQ:BTMD) issued its quarterly earnings data on Tuesday, March, 12th. The company reported $0.14 earnings per share for the quarter, topping the consensus estimate of $0.08 by $0.06. The business earned $45.70 million during the quarter, compared to the consensus estimate of $45.50 million. biote had a net margin of 4.30% and a negative trailing twelve-month return on equity of 36.67%.

What guidance has biote issued on next quarter's earnings?

biote updated its FY 2024 earnings guidance on Wednesday, May, 8th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $200.0 million-$204.0 million, compared to the consensus revenue estimate of $202.3 million.

Who are biote's major shareholders?

biote's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (1.88%), Wasatch Advisors LP (0.90%) and Acadian Asset Management LLC (0.16%). Insiders that own company stock include Mary Elizabeth Conlon, Roystone Capital Management Lp and Samar Jagat Kamdar.
View institutional ownership trends

How do I buy shares of biote?

Shares of BTMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:BTMD) was last updated on 5/23/2024 by Staff

From Our Partners